Bismuth subsalicylate
/ / (bismuth subsalicylate) is a small molecule pharmaceutical. Bismuth subsalicylate was first approved as Helidac on 1996-08-15. It is used to treat bacillary dysentery, diarrhea, dyspepsia, escherichia coli infections, and helicobacter infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bismuth subsalicylate
+
Metronidazole
+
Tetracycline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HELIDAC | Casper Pharma | N-050719 DISCN | 1996-08-15 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 24 / 7 life stomach relief | OTC monograph final | 2023-07-19 |
| anti-diarrheal | OTC monograph final | 2023-03-25 |
| bismatrol | C200263 | 2024-01-01 |
| bismuth | OTC monograph final | 2022-06-11 |
| bismuth chewable | OTC monograph final | 2016-12-19 |
| bismuth subsalicylate | C200263 | 2024-02-01 |
| bismuth subsalicylate 262 mg | OTC monograph final | 2023-03-29 |
| bismuth subsalicylate/metronidazole/tetracycline hydrochloride | ANDA | 2019-11-24 |
| bismutina | OTC monograph final | 2021-04-28 |
| chewable | OTC monograph final | 2011-11-26 |
Show 114 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
59 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Constipation | D003248 | HP_0002019 | K59.0 | — | 2 | 2 | 5 | 1 | 9 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | 4 | — | 4 |
| Analgesia | D000698 | — | — | — | — | — | 1 | 2 | 3 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | 1 | 1 | 1 | 3 |
| Ileus | D045823 | — | K56.7 | 1 | — | — | 1 | — | 2 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | 1 | — | 1 |
| Flatulence | D005414 | — | R14.3 | — | — | — | 1 | — | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | 1 | — | 1 |
| Clostridium infections | D003015 | EFO_1000874 | A05.2 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | 1 | 1 | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 1 | — | — | 1 |
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | 1 | 2 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 1 | — | — | — | 2 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | — | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | 1 | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | — | 1 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | — | — | — | — | 1 | 1 |
| Microbiota | D064307 | — | — | — | — | — | — | 1 | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | — | — | — | 1 | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 1 | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | — | 1 | 1 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | — | 1 | 1 |
| Macular edema | D008269 | — | — | — | — | — | — | 1 | 1 |
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bismuth subsalicylate |
| INN | — |
| Description | Bismuth subsalicylate is a bismuth salt of salicylic acid. It is a member of salicylates and a bismuth coordination entity. |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (salicylic acid derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 14882-18-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1120 |
| ChEBI ID | 261649 |
| PubChem CID | 16682734 |
| DrugBank | DB01294 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Bismuth subsalicylate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,489 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bismuth subsalicylate/metronidazole/tetracycline hydrochloride, Helidac therapy
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
649 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use